Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention

Authors

  • MM Haq Ibrahim Cardiac Hospital & Research Institute, Shahbag, Dhaka
  • CH Ahsan Department of Cardiology, University Medical Center, Las Vegas
  • MN Amin Ibrahim Cardiac Hospital & Research Institute, Shahbag, Dhaka
  • MR Karim Ibrahim Cardiac Hospital & Research Institute, Shahbag, Dhaka
  • ML Ali Ibrahim Cardiac Hospital & Research Institute, Shahbag, Dhaka
  • SR Khan Ibrahim Cardiac Hospital & Research Institute, Shahbag, Dhaka
  • MZ Chowdhury Ibrahim Cardiac Hospital & Research Institute, Shahbag, Dhaka
  • M Mansur Ibrahim Cardiac Hospital & Research Institute, Shahbag, Dhaka
  • MH Millat Ibrahim Cardiac Hospital & Research Institute, Shahbag, Dhaka
  • MA Rashid Ibrahim Cardiac Hospital & Research Institute, Shahbag, Dhaka

DOI:

https://doi.org/10.3329/bmrcb.v39i3.20315

Abstract

Dual antiplatelet treatment (DAPT) with aspirin and clopidogrel is vital after percutaneous coronary intervention (PCI). Clopidogrel and prasugrel act on P2Y12 platelet surface receptors. Both these P2Y12 inhibitors are pro-drugs and depend on cytochrome system of the liver for their conversion to active metabolite. There is growing concern regarding suboptimal response in platelet inhibition by clopidogrel. Verify Now system got approval by Federal Drug Administration, USA, for assessing platelet function as its result is almost comparable to gold standard Light Transmission Aggregometry (LTA). There are no data on the prevalence of clopidogrel resistance in Bangladeshi population. Prasugrel, as an antiplatelet drug, is a newer introduction in this country. This study will show light on the efficacy of these drugs on our population especially in patients who undergo PCI where DAPT is mandatory. A total 120 (60 diabetics ) patients with Acute Coronary Syndrome (ACS), were alternatively given 600 mg clopidogrel loading dose (LD) followed by 75 mg maintenance dose (MD) daily or 60 mg LD of prasugrel followed by 10 mg MD daily. Five samples of blood were taken at different time intervals over a period of 2 weeks. Measurement of percent inhibition of P2Y12 was done by VerifyNow. Patients who showed less than 20% inhibition (clopidogrel resistant) at any stage were switched to prasugrel. The outcomes of clopidogrel, prasugrel and clopidogrel switched to prasugrel groups were then compared. Nearly half (46.7%) of the patients in the clopidogrel group was found resistant to the drug as opposed to none in the prasugrel group. No difference was found between diabetic and non-diabetic subjects with respect to drug resistance. Intracoronary blood samples showed high degree of platelet inhibition with prasugrel. There was a gradual decline of platelet inhibition over two weeks with prasugrel. Almost fifty percent of the population is clopidogrel resistant in our study. Prasugrel is a much more potent antiplatelet drug and should be preferred in patients undergoing PCI. Prasugrel may also show resistance over time.

DOI: http://dx.doi.org/10.3329/bmrcb.v39i3.20315

Bangladesh Med Res Counc Bull 2013; 39: 139-145

Downloads

Download data is not yet available.
Abstract
824
PDF
768

Downloads

Published

2014-09-04

How to Cite

Haq, M., Ahsan, C., Amin, M., Karim, M., Ali, M., Khan, S., Chowdhury, M., Mansur, M., Millat, M., & Rashid, M. (2014). Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention. Bangladesh Medical Research Council Bulletin, 39(3), 139–145. https://doi.org/10.3329/bmrcb.v39i3.20315

Issue

Section

Research Papers